HIV Medications with Pre-exposure Prophylaxis (PrEP) Use Zero Dollar Cost Share Descovy 200/25 mg, generic tenofovir fumarate 300 mg, brand Truvada 200/300 mg, and brand Viread 300 mg
Defines coverage at zero dollar cost share for pre-exposure prophylaxis (PrEP) medications Descovy 200/25 mg, generic tenofovir 300 mg, brand Truvada 200/300 mg, and brand Viread 300 mg for UnitedHealthcare commercial plans; includes approval duration and default to standard plan coverage when criteria not met.
Added coverage for brand Truvada and brand Viread (11/2024).
Annual review (10/2023) updated criteria with no change to clinical intent.
Added Descovy strength indicated for PrEP (5/2022).
Updated references (2/2022, 12/2020).
Annual review (12/2025) noted no changes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.